- Previous Close
1.1400 - Open
1.1200 - Bid 1.1200 x 100
- Ask 1.2300 x 100
- Day's Range
1.1000 - 1.2000 - 52 Week Range
1.1000 - 5.9900 - Volume
75,019 - Avg. Volume
134,498 - Market Cap (intraday)
12.851M - Beta (5Y Monthly) 1.52
- PE Ratio (TTM)
-- - EPS (TTM)
-1.0700 - Earnings Date May 13, 2025 - May 19, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.33
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
markertherapeutics.comRecent News: MRKR
View MorePerformance Overview: MRKR
Trailing total returns as of 4/2/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRKR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRKR
View MoreValuation Measures
Market Cap
12.21M
Enterprise Value
-5.91M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.64
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-179.71%
Return on Assets (ttm)
-41.92%
Return on Equity (ttm)
-79.76%
Revenue (ttm)
5.4M
Net Income Avi to Common (ttm)
-9.63M
Diluted EPS (ttm)
-1.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
9M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-5.25M